Dr. Pennell is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
9500 Euclid Ave
CA-6
Cleveland, OH 44195Phone+1 216-445-9282Fax+1 216-444-9464- Is this information wrong?
Summary
- I am the Vice Chair of Clinical Research as well Director of the lung cancer medical oncology program at the Cleveland Clinic Taussig Cancer Institute, where I specialize in the care of patients with thoracic malignancies, including lung cancer and mesothelioma. I also perform clinical research in lung cancer and am active in healthcare social media.
I am also active in patient and graduate medical education. I serve as Editor in Chief of the American Society of Clinical Oncology (ASCO) Education Book.
Education & Training
- Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2005 - 2007
- Brigham and Women's HospitalResidency, Internal Medicine, 2002 - 2005
- University of Florida College of MedicineClass of 2002
- University of FloridaPhD, Neuroscience, 1993 - 1998
- University of North CarolinaBS, Biology, 1989 - 1993
Certifications & Licensure
- OH State Medical License 2008 - 2026
- MA State Medical License 2004 - 2009
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Editor in Chief, ASCO Educational Book ASCO
- Associate Editor, ASCO Educational Book ASCO, 2012-2022
- Elected to Nominating Committee ASCO
- Join now to see all
Clinical Trials
- Erlotinib, Paclitaxel, and Carboplatin Combined With Radiation Therapy for Stage III Non-Small Cell Lung Cancer Start of enrollment: 2005 Oct 01
- Pemetrexed or Docetaxel With or Without Erlotinib in Stage IIIB or Stage IV Non-Small Cell Lung Cancer Start of enrollment: 2008 Jan 01
- Sorafenib, Cisplatin, and Etoposide in Treating Patients With Extensive-Stage Small Cell Lung Cancer Start of enrollment: 2008 Jul 01
- Join now to see all
Publications & Presentations
PubMed
- 1331 citationsCell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer.Katherine A Hoadley, Christina Yau, Toshinori Hinoue, Denise M. Wolf, Alexander J. Lazar
Cell. 2018-04-05 - 1204 citationsClinical impact of COVID-19 on patients with cancer (CCC19): a cohort study.Nicole M. Kuderer, Toni K. Choueiri, Dimpy P. Shah, Yu Shyr, Samuel M. Rubinstein
Lancet. 2020-06-20 - 25 citationsPhase Ib Study of Crizotinib plus Pembrolizumab in Patients with Previously Untreated Advanced Non-Small Cell Lung Cancer with ALK Translocation.Sandip Pravin Patel, Suchita Pakkala, Nathan A. Pennell, Karen L. Reckamp, Silvana Lanzalone
The Oncologist. 2020-07-01
Journal Articles
- Adjuvant Targeted Therapy for Patients with Epidermal Growth Factor Receptor–Mutant Lung CancerNathan Pennell, MD, JAMA Oncology
- ALK Status Testing in Non-small Cell Lung Carcinoma by FISH on ThinPrep Slides with Cytology MaterialMinca EC, Lanigan C, Reynolds JP, Wang Z, Ma PC, Cicenia J, Almeida FA, Pennell NA, Tubbs RR, J Thor Onc, 1/1/2014
- High MET Receptor Expression but not Gene Amplification in ALK 2p23 Rearrangement Positive Non-Small Cell Lung CancerFeng Y, Minca EC, Lanigan C, Liu A, Zhang W, Yin L, Pennell NA, Farver C, Tubbs R, Ma PC, J Thor Onc, 1/1/2014
- Join now to see all
Books/Book Chapters
Abstracts/Posters
- Molecular Subtyping to Predict Risk of Venous Thromboembolism in Patients with Advanced Lung Adenocarcinoma: A Cohort StudyNathan A Pennell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- EGFR Mutational Analysis by Allele Specific PCR on Fine Needle Aspiration and Biopsy Derived Samples of Non-Small Cell Lung CarcinomaMinca EC, Brainard J, MacNamara S, Farver C, Ma PC, Arrossi V, Pennell N, Tubbs RR, USCAP Annual Meeting, 1/1/2014
- Circulating Tumor Cells Enrichment and Characterization in ALK-translocation Positive Lung CancerPC Ma, L Yin, P Joshi, Y Feng, B Jacobs, W Zhang, M Shapiro, M McNamara, N Hashemi Sadraei, N Pennell, E B, M Zborowski, Proc Amer Soc Clin Onc, 1/1/2014
- Join now to see all
Lectures
- Guidelines, Barriers, Access to Molecular Testing in NSCLCASCO Annual Meeting 2019 - Chicago, IL - 5/31/2019
- Assessment and Diagnostics of Newly Diagnosed Patients With Advanced Non-Small Cell Lung Cancer2018 ASCO Annual Meeting - Chicago, Illinois - 06/1/2018
- Circulating Tumor Cells Detection and Molecular Characterization of ALK(2p23)-Fusion Non-Small Cell Lung CancerSydney - 1/1/2013
- Join now to see all
Other
- Treatment of a Patient with Metastatic Non-Small-Cell Lung Cancer and Adenocarcinoma HistologyPennell, N.A. and Perez-Soler, R., Oncology Consultations
http://www.cancerlearning.com/index.cfm/fuseaction/publication.showOverview/id/9/publication_id/330
1/1/2009 - Study Guide for "Voices from the Lived World of Illness", an Interactive DVD about Terminal Cancer Patients Created by the Institute of Medical HumanismSchapira, L., Pennell, N.A., Bandman, B.M., Bandman, C.
Burlington, VT - 1/1/2006
Authored Content
- Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung CancerAugust 2020
- Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung CancerAugust 2020
- Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung CancerAugust 2020
Press Mentions
- Advances in Non-Small-Cell Lung Cancer TreatmentDecember 12th, 2022
- IO Combo Therapy with Durvalumab for the Win in Advanced NSCLC?September 23rd, 2022
- Lung Cancer Is Not Just a Smoker’s Disease, Cleveland Clinic Expert Cautions Ahead of World Lung Cancer DayJuly 31st, 2022
- Join now to see all
Professional Memberships
- Member
Hospital Affiliations
- Cleveland ClinicCleveland, Ohio
External Links
- CCF Websitehttp://my.clevelandclinic.org/staff_directory/staff_display.aspx?doctorid=8882
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: